How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway

BJU Int. 2024 Feb:133 Suppl 3:13-14. doi: 10.1111/bju.16175. Epub 2023 Oct 4.

Gideon Ptasznik^{1

2

3}, Brian D Kelly^{1

4}, Declan Murphy¹, Nathan Lawrentschuk¹, Veeru Kasivisvanathan^{1

5}, Mark Page⁶, Sean Ong¹, Daniel Moon^{4

7}

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
³ Young Urology Research Organisation, Melbourne, VIC, Australia.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
⁵ Division of Surgery and Interventional Science, University College London, London, UK.
⁶ Division of Medical Imaging, St. Vincents Hospital (Melbourne Victoria), Melbourne, VIC, Australia.
⁷ Royal Melbourne Hospital Clinical School, University of Melbourne, Melbourne, VIC, Australia.

No abstract available

MeSH terms